Related Experiment Video

Updated: Oct 31, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target

Saiful Islam1, Shudong Wang1, Nikola Bowden2

  • 1Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA, 500, Australia.

British Journal of Clinical Pharmacology
|June 30, 2021
PubMed

Insights

Drug repurposing offers a strategic approach to cancer therapeutics by identifying existing non-cancer drugs that inhibit kinases. This method accelerates the development of novel cancer treatments, leveraging known drug safety profiles.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Discovery

Background:

  • Drug repurposing is a valuable strategy for expanding cancer therapeutics pipelines.
  • Historically, drug repurposing relied on serendipity, but systematic approaches are now prevalent.
  • Kinases are critical anti-cancer targets, with many existing drugs exhibiting kinase inhibitory off-target effects.

Purpose of the Study:

  • To review the advantages, rationale, barriers, and opportunities of drug repurposing in cancer therapy.
  • To highlight the potential of repurposing non-cancer drugs and existing kinase inhibitors for oncology.
  • To provide examples of drugs with anti-cancer kinase-related activity.

Main Methods:

  • Systematic identification of repurposing opportunities through drug- or target-centric approaches.
  • Mining commercial drug databases for kinase inhibitors.
  • Comprehensive kinome profiling to identify new kinase targets for existing inhibitors.

Main Results:

  • Drug repurposing accelerates the identification of trial-ready cancer therapeutics.
  • Systematic approaches enhance the efficiency of finding repurposed drugs.
  • Kinase inhibition is a key mechanism for many repurposed anti-cancer agents.

Conclusions:

  • Drug repurposing is a vital component of modern cancer drug development.
  • Leveraging off-target kinase inhibition and kinome profiling can yield effective cancer treatments.
  • Repurposing existing drugs offers a faster, more cost-effective route to clinical validation.
Keywords:
cancerdrug developmentkinaseoncologyrepurposing

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K